{"id":634148,"date":"2023-01-16T16:32:01","date_gmt":"2023-01-16T16:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634148"},"modified":"2023-01-16T16:32:01","modified_gmt":"2023-01-16T16:32:01","slug":"diabetic-retinopathy-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-retinopathy-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634148.html","title":{"rendered":"Diabetic Retinopathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1673848953.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetic Retinopathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1673848953.jpeg\" alt=\"Diabetic Retinopathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Diabetic Retinopathy Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s &#8216;Diabetic Retinopathy Pipeline Insight 2023&#8217; report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Retinopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Retinopathy pipeline domain.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&#8216;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><strong>Diabetic Retinopathy Pipeline Insight 2023<\/strong><\/a><strong>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Retinopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Retinopathy pipeline domain.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Diabetic Retinopathy Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 60+ Diabetic Retinopathy pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetic Retinopathy market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Diabetic Retinopathy companies developing novel drug candidates to improve the Diabetic Retinopathy treatment landscape include <strong>Kodiak Sciences, Novartis, Regenxbio Inc., <\/strong>and others.<\/li>\n<li>Promising Diabetic Retinopathy pipeline therapies in various stages of development include <strong>KSI-301, Brolucizumab, RGX 314<\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Diabetic Retinopathy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Diabetic retinopathy is a diabetes complication that affects eyes. It&#8217;s caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina).<\/p>\n<p style=\"text-align: justify;\">At first, diabetic retinopathy might cause no symptoms or only mild vision problems. But it can lead to blindness.<\/p>\n<p style=\"text-align: justify;\">The condition can develop in anyone who has type 1 or type 2 diabetes. The longer you have diabetes and the less controlled your blood sugar is, the more likely you are to develop this eye complication.<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Retinopathy Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>RGX 314: Regenxbio Inc.<\/strong><\/p>\n<p style=\"text-align: justify;\">RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for formation of new leaky blood vessels and retinal fluid accumulation. The company is currently enrolling patients in ALTITUDETM, a Phase II trial for the treatment of diabetic retinopathy using suprachoroidal delivery of RGX-314.<\/p>\n<p style=\"text-align: justify;\">Discover more about the emerging Diabetic Retinopathy drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><strong>Diabetic Retinopathy Treatment Drugs<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Retinopathy Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Kodiak Sciences<\/li>\n<li>Novartis<\/li>\n<li>Regenxbio Inc.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Diabetic Retinopathy Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>KSI-301<\/li>\n<li>Brolucizumab<\/li>\n<li>RGX 314<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Diabetic Retinopathy Pipeline Therapeutics Assessment<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By development stage<\/strong><\/li>\n<li><strong>By product type<\/strong><\/li>\n<li><strong>By route of administration<\/strong><\/li>\n<li><strong>By molecule type<\/strong><\/li>\n<li><strong>By MOA type&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Diabetic Retinopathy Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Diabetic Retinopathy Companies<\/strong>: Kodiak Sciences, Novartis, Regenxbio Inc, and others<\/li>\n<li><strong>Key Diabetic Retinopathy Pipeline Therapies<\/strong>: KSI-301, Brolucizumab, RGX 314, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out more about the Diabetic Retinopathy treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><strong>Diabetic Retinopathy Clinical Trials<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetic-retinopathy-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetic-retinopathy-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diabetic Retinopathy Pipeline Insights DelveInsight\u2019s &#8216;Diabetic Retinopathy Pipeline Insight 2023&#8217; report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Retinopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-retinopathy-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634148.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-634148","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=634148"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634148\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=634148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=634148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=634148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}